SK Bioscience Vaccine Goes to Phase-3 Clinical Trial

  • By Bae Jun-yong

    August 11, 2021 11:49

    SK Bioscience is about to start the phase 3 clinical trial of its coronavirus vaccine, a first for a Korean vaccine developer.

    The Ministry of Food and Drug Safety on Tuesday said it approved the phase 3 study of GBP510, a vaccine developed by SK Bioscience. GBP510 is a protein-based vaccine like Novavax of the U.S.

    SK Bioscience has received some W200 billion for development from the Coalition for Epidemic Preparedness Innovations, a global partnership founded by Bill and Melinda Gates, and W3 billion from the government (US$1=W1,151).

    According to the ministry, the results of the phase 1 clinical trial were positive, and an interim report on the study of 80 adults shows that more than five times as many neutralizing antibodies were formed in all subjects than in those who had been cured of COVID-19. A phase 2 study of 240 adults is underway.

    The phase 3 clinical trial is being conducted in comparison with Pfizer or Moderna vaccines to gauge safety and efficacy.

    SK Bioscience will give GBP510 shots to 3,000 people and AstraZeneca jabs to 990 others in Korea, Southeast Asia and Eastern Europe.

    • Copyright © Chosunilbo &
    Previous Next
    All Headlines Back to Top